ACCUSTEM SCIENCES, INC.
Moat Score — AccuStem Sciences, Inc.
Total Moat Score
3 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Owns/licenses patented microRNA (MSC) and gene-expression (StemPrintER) diagnostic IP validated in thousands of patients, but products are not yet commercially launched or broadly patent-protected against workarounds. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Pre-commercial with no manufacturing or lab-operations scale; outsources CLIA testing to a partner lab, so no demonstrated cost edge exists. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | No launched product and no established payor reimbursement, so the company has no pricing power today. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Diagnostic tests do not benefit from user network effects; value comes from clinical validation data, not user adoption feedback loops. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once a diagnostic becomes embedded in a physician's standard workflow it can be sticky, but AccuStem has not yet achieved that clinical adoption to generate real switching costs. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | Two-employee, pre-revenue company with no scale in a market already served by entrenched competitors like Exact Sciences' Oncotype DX. |